1 Min Read
BRUSSELS, Feb 25 (Reuters) - Ablynx NV : * Ablynx and Spirogen enter into a research collaboration to evaluate the
potential of novel toxin-nanobody drug conjugates in cancer
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.